Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies

Vista senzilla d'ítem
dc.contributor.authorCalvet, Xavier
dc.contributor.authorCarpio, Daniel
dc.contributor.authorRodriguez Lago, Iago
dc.contributor.authorGarcia Vicuña, Rosario
dc.contributor.authorBarreiro de Acosta, Manuel
dc.contributor.authorJuanola, Xavier
dc.contributor.authorAguas, Mariam
dc.contributor.authorCastillo, Concepción
dc.contributor.authorGratacós Masmitjà, Jordi
dc.date.accessioned2022-02-11T16:44:29Z
dc.date.available2022-02-11T16:44:29Z
dc.date.issued2021
dc.description.abstractPatients with certain immune-mediated inflammatory diseases, such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), have an increased risk of severe infectious diseases than the general population, which are mainly associated with the immunosuppressive treatments that they receive. These treatments act on the immune system through different mechanisms, causing different degrees of immunosuppression and a variable risk depending on whether the pathogen is a virus, bacteria or fungus. This article reviews the most relevant literature on the subject, which was selected and discussed by a panel of experts. The aim of this article is to review the risk of infections in patients with IBD and RA, and the potential preventive measures. (C) 2021 The Author(s). Published by Elsevier Espana, S.L.U.ca
dc.format.extent12 p.
dc.format.mimetypeapplication/pdf
dc.identifier.citationCalvet, X., Carpio, D., Rodríguez-Lago, I., García-Vicuña, R., Barreiro-de-Acosta, M., Juanola, X., ... & Gratacós, J. (2021). Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies. Gastroenterología y Hepatología (English Edition), 44(8), 587-598.ca
dc.identifier.issn2444-3824
dc.identifier.pmid33640469
dc.identifier.urihttps://hdl.handle.net/2445/183106
dc.language.isoengca
dc.publisherElsevierca
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.gastrohep.2021.01.007
dc.relation.ispartofGastroenterología y Hepatología (English Edition), 2021, vol 44, num 8, p. 587-598.
dc.relation.urihttps://doi.org/10.1016/j.gastrohep.2021.01.007
dc.rightscc by (c) Calvet, Xavier et al, 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationArtritis reumatoide
dc.subject.classificationMalalties inflamatòries intestinals
dc.subject.classificationImmunosupressió
dc.subject.otherRheumatoid arthritis
dc.subject.otherInflammatory bowel diseases
dc.subject.otherImmunosuppression
dc.titleRisk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategiesca
dc.typeinfo:eu-repo/semantics/articleca
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Miniatura
Nom:
1-s2.0-S021057052100056X-main.pdf
Mida:
476.78 KB
Format:
Adobe Portable Document Format
Descripció:
Descarregar

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))